Proteomic identification of biomarkers of vascular injury

American Journal of Translational Research

Volumn 3, Issue 2, 2011, Pages 139-148

  Huang, Ngan F ^a,d   Kurpinski, Kyle ^a   Fang, Qizhi ^b   Lee, Randall J ^a,b   Li, Song ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of California at Berkeley   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aldolase; Angioplasty; Apolipoprotein E; Atherosclerosis; Plasma marker; Proteomic profiling; Vascular injury; Vitamin D binding protein

Indexed keywords

APOLIPOPROTEIN E; BIOLOGICAL MARKER; FRUCTOSE BISPHOSPHATE ALDOLASE; FRUCTOSE BISPHOSPHATE ALDOLASE ISOENZYME; PLASMA PROTEIN; PROTEOME; UNCLASSIFIED DRUG; VITAMIN D BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL INJURY; CAROTID ARTERY INJURY; CONTROLLED STUDY; IMMUNOBLOTTING; MALE; MASS SPECTROMETRY; NEOINTIMA; NONHUMAN; PROTEIN EXPRESSION; PROTEOMICS; RAT; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANIMALIA; RATTUS;

EID: 79952908399     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell C, Roger V, Sorlie P, Steinberger J, Thom T, Wilson M and Hong Y. Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117: e25-146.
2. Glass CK and Witztum JL. Atherosclerosis. the road ahead. Cell 2001; 104: 503-516.
3. Mateos-Caceres PJ, Garcia-Mendez A, Lopez Farre A, Macaya C, Nunez A, Gomez J, Alonso-Orgaz S, Carrasco C, Burgos ME, de Andres R, Granizo JJ, Farre J and Rico LA. Proteomic analysis of plasma from patients during an acute coronary syndrome. J Am Coll Cardiol 2004; 44: 1578-1583.
4. Hori T, Naishiro Y, Sohma H, Suzuki N, Hatakeyama N, Yamamoto M, Sonoda T, Mizue Y, Imai K, Tsutsumi H and Kokai Y. CCL8 is a potential molecular candidate for the diagnosis of graftversus-host disease. Blood 2008; 111: 4403-4412.
5. Wilson AM, Kimura E, Harada RK, Nair N, Narasimhan B, Meng XY, Zhang F, Beck KR, Olin JW, Fung ET and Cooke JP. Beta2-microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies. Circulation 2007; 116: 1396-1403.
6. Kim SS, Kim MH, Shin BK, Na HJ, Choi JY, Kee MK, Chong SA and Nam MJ. Different isoforms of apolipoprotein AI present heterologous posttranslational expression in HIV infected patients. J Proteome Res 2007; 6: 180-184.
7. Shagdarsuren E, Bidzhekov K, Djalali-Talab Y, Liehn EA, Hristov M, Matthijsen RA, Buurman WA, Zernecke A and Weber C. C1-esterase inhibitor protects against neointima formation after arterial injury in atherosclerosis-prone mice. Circulation 2008; 117: 70-78.
8. Bailey SR, Mitra S, Flavahan S, Bergdall VK and Flavahan NA. In vivo endothelial denudation disrupts smooth muscle caveolae and differentially impairs agonist-induced constriction in small arteries. J Cardiovasc Pharmacol 2007; 49: 183-190.
9. Liu P, Patil S, Rojas M, Fong AM, Smyth SS and Patel DD. CX3CR1 deficiency confers protection from intimal hyperplasia after arterial injury. Arterioscler Thromb Vasc Biol 2006; 26: 2056-2062.
10. Chadjichristos CE, Matter CM, Roth I, Sutter E, Pelli G, Luscher TF, Chanson M and Kwak BR. Reduced connexin43 expression limits neointima formation after balloon distension injury in hypercholesterolemic mice. Circulation 2006; 113: 2835-2843.
11. Marshall J, Kupchak P, Zhu W, Yantha J, Vrees T, Furesz S, Jacks K, Smith C, Kireeva I, Zhang R, Takahashi M, Stanton E and Jackowski G. Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction. J Proteome Res 2003; 2: 361-372.
12. Mayr M, Zhang J, Greene AS, Gutterman D, Perloff J and Ping P. Proteomics-based development of biomarkers in cardiovascular disease: mechanistic, clinical, and therapeutic insights. Mol Cell Proteomics 2006; 5: 1853-1864.
13. Mayr M, Yusuf S, Weir G, Chung YL, Mayr U, Yin X, Ladroue C, Madhu B, Roberts N, De Souza A, Fredericks S, Stubbs M, Griffiths JR, Jahangiri M, Xu Q and Camm AJ. Combined metabolomic and proteomic analysis of human atrial fibrillation. J Am Coll Cardiol 2008; 51: 585-594.
14. Leidenfrost JE, Khan MF, Boc KP, Villa BR, Collins ET, Parks WC, Abendschein DR and Choi ET. A model of primary atherosclerosis and postangioplasty restenosis in mice. Am J Pathol 2003; 163: 773-778.
15. de la Fuente J, Blouin EF, Manzano-Roman R, Naranjo V, Almazan C, Perez de la Lastra JM, Zivkovic Z, Jongejan F and Kocan KM. Functional genomic studies of tick cells in response to infection with the cattle pathogen, Anaplasma marginale. Genomics 2007; 90: 712-722.
16. Corena-McLeod Mdel P, Oliveros A, Charlesworth C, Madden B, Liang YQ, Boules M, Shaw A, Williams K and Richelson E. Paliperidone as a mood stabilizer: a pre-frontal cortex synaptoneurosomal proteomics comparison with lithium and valproic acid after chronic treatment reveals similarities in protein expression. Brain Res 2008; 1233: 8-19.
17. Mo W and Karger BL. Analytical aspects of mass spectrometry and proteomics. Curr Opin Chem Biol 2002; 6: 666-675.
18. Rabilloud T. Two-dimensional gel electrophoresis in proteomics: old, old fashioned, but it still climbs up the mountains. Proteomics 2002; 2: 3-10.
19. Patterson SD and Aebersold RH. Proteomics: the first decade and beyond. Nat Genet 2003; 33 Suppl: 311-323.
20. MacCoss MJ and Yates JR, 3rd. Proteomics: analytical tools and techniques. Curr Opin Clin Nutr Metab Care 2001; 4: 369-375.
21. Yarmush ML and Jayaraman A. Advances in proteomic technologies. Annu Rev Biomed Eng 2002; 4: 349-373.
22. Srinivas PR, Verma M, Zhao Y and Srivastava S. Proteomics for cancer biomarker discovery. Clin Chem 2002; 48: 1160-1169.
23. Witzmann FA and Li J. Cutting-edge technology. II. Proteomics: core technologies and applications in physiology. Am J Physiol Gastrointest Liver Physiol 2002; 282: G735-741.
24. Lilley KS, Razzaq A and Dupree P. Twodimensional gel electrophoresis: recent advances in sample preparation, detection and quantitation. Curr Opin Chem Biol 2002; 6: 46-50.
25. Meier U, Gressner O, Lammert F and Gressner AM. Gc-globulin: roles in response to injury. Clin Chem 2006; 52: 1247-1253.
26. Gomme PT and Bertolini J. Therapeutic potential of vitamin D-binding protein. Trends Biotechnol 2004; 22: 340-345.
27. White P and Cooke N. The multifunctional properties and characteristics of vitamin D-binding protein. Trends Endocrinol Metab 2000; 11: 320-327.
28. Lee WM and Galbraith RM. The extracellular actin-scavenger system and actin toxicity. N Engl J Med 1992; 326: 1335-1341.
29. Schellenberg D, Pare PD, Weir TD, Spinelli JJ, Walker BA and Sandford AJ. Vitamin D binding protein variants and the risk of COPD. Am J Respir Crit Care Med 1998; 157: 957-961.
30. Yamamoto N and Naraparaju VR. Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D-binding protein-derived macrophage activating factor. Cancer Res 1997; 57: 2187-2192.
31. Dahl B, Schiodt FV, Rudolph S, Ott P, Kiaer T and Heslet L. Trauma stimulates the synthesis of Gcglobulin. Intensive Care Med 2001; 27: 394-399.
32. Miserez AR, Scharnagl H, Muller PY, Mirsaidi R, Stahelin HB, Monsch A, Marz W and Hoffmann MM. Apolipoprotein E3Basel: new insights into a highly conserved protein region. Eur J Clin Invest 2003; 33: 677-685.
33. Moghadasian MH, McManus BM, Nguyen LB, Shefer S, Nadji M, Godin DV, Green TJ, Hill J, Yang Y, Scudamore CH and Frohlich JJ. Pathophysiology of apolipoprotein E deficiency in mice: relevance to apo E-related disorders in humans. Faseb J 2001; 15: 2623-2630.
34. Ghiselli G, Schaefer EJ, Gascon P and Breser HB, Jr. Type III hyperlipoproteinemia associated with apolipoprotein E deficiency. Science 1981; 214: 1239-1241.
35. Fazio S, Babaev VR, Murray AB, Hasty AH, Carter KJ, Gleaves LA, Atkinson JB and Linton MF. Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages. Proc Natl Acad Sci U S A 1997; 94: 4647-4652.
36. Poirier J, Delisle MC, Quirion R, Aubert I, Farlow M, Lahiri D, Hui S, Bertrand P, Nalbantoglu J, Gilfix BM and Gauthier S. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A 1995; 92: 12260-12264.
37. Wientgen H, Thorngate FE, Omerhodzic S, Rolnitzky L, Fallon JT, Williams DL and Fisher EA. Subphysiologic apolipoprotein E (ApoE) plasma levels inhibit neointimal formation after arterial injury in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2004; 24: 1460-1465.
38. Hori K, Mukai T, Joh K, Arai Y, Sakakibara M and Yatsuki H. Structure and expression of human and rat aldolase isozyme genes: multiple mRNA species of aldolase A produced from a single gene. Isozymes Curr Top Biol Med Res 1987; 14: 153-175.
39. Hers HG and Kusaka T. [The metabolism of fructose-1-phosphate in the liver.]. Biochim Biophys Acta 1953; 11: 427-437.
40. Maffia P, Grassia G, Di Meglio P, Carnuccio R, Berrino L, Garside P, Ianaro A and Ialenti A. Neutralization of interleukin-18 inhibits neointimal formation in a rat model of vascular injury. Circulation 2006; 114: 430-437.
41. Strijbos MH, Rao C, Schmitz PI, Kraan J, Lamers CH, Sleijfer S, Terstappen LW and Gratama JW. Correlation between circulating endothelial cell counts and plasma thrombomodulin levels as markers for endothelial damage. Thromb Haemost 2008; 100: 642-647.
42. Drosopoulos JH, Kraemer R, Shen H, Upmacis RK, Marcus AJ and Musi E. Human solCD39 inhibits injury-induced development of neointimal hyperplasia. Thromb Haemost 103: 426-434.